20 июл. 2023 г. · This guideline provides an evidenced-based and patient-centered approach to management of patients with chronic coronary disease.

Class I recommendation to assess, monitor, and address SDOH and disparities impacting HF patients with multidisciplinary management, across phases of care.

1 апр. 2022 г. · The 2022 guideline is intended to provide patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with heart failure.

All individuals with a diagnosis of HFpEF should be treated with an SGLT2i, with the goal of reducing cardiovascular death/HF hospitalization and improving ...

25 авг. 2023 г. · The aim of this ESC guideline is to help health professionals manage people with heart failure (HF) according to the best available evidence.

The AHA/ACC/HFSA guidelines make a moderate-strength recommendation that “excess sodium” be avoided, with no particular limit suggested. However, separate from ...

Access the latest cardiovascular guidelines & statements from the AHA on Professional Heart Daily. Stay up-to-date on best practices in cardiovascular care.

19 апр. 2023 г. · Management of HFpEF centers around managing comorbidities first including hypertension, obesity, diabetes, AF, and sleep apnea. Hypertension ...

The recommendations of the 2022 AHA/ACC/HFSA Guideline includes the use of SGLT2is and also the treatment of hypertension and cardiovascular disease.

The 2022 AHA/ACC/HFSA HF guideline recommends sacubitril/valsartan as a Class I, Level of Evidence: A therapy to reduce the risk of HF hospitalization and CV ...